TargetBeta
CLDN6
claudin 6 · Claudins
5 programs in company-led studies act on CLDN6, from 5 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| ixotatug vedotinrule | TORL Biotherapeutics | phase 2 | 33 running | – | NCIt |
| CLDN6 RNA-LPX Vaccinerule | BioNTech | phase 2 | 10 running | – | NCIt |
| Anti-CLDN6/CD3 Bispecific Antibody XmAb541rule | Xencor | phase 1 | 22 running | CD3E | NCIt |
| Anti-Claudin 6 Antibody-drug Conjugate AT03-65rule | Axcynsis Therapeutics Pte | phase 1 | 11 running | – | NCIt |
| Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455rule | BeOne Medicines | phase 1 | 11 running | CD3E | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Ovarian Neoplasms, 2 programs
- Carcinoma, Ovarian Epithelial, 1 program
- Fallopian Tube Neoplasms, 1 program
- Neoplasm Metastasis, 1 program
- Testicular Germ Cell Tumor, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Oct 2027ixotatug vedotin · TORL Biotherapeutics · phase 2 · NCT06690775
- Dec 2027Anti-CLDN6/CD3 Bispecific Antibody XmAb541 · Xencor · phase 1 · NCT06276491
- Dec 2027Anti-Claudin 6 Antibody-drug Conjugate AT03-65 · Axcynsis Therapeutics Pte · phase 1 · NCT06809114
- Apr 29, 2028Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455 · BeOne Medicines · phase 1 · NCT06803680
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.